Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$41.36
-5.2%
$60.06
$37.43
▼
$95.49
$5.85B1.342.27 million shs3.91 million shs
Incyte Corporation stock logo
INCY
Incyte
$114.63
-1.1%
$118.63
$89.25
▼
$132.60
$23.37B0.781.72 million shs1.54 million shs
Insmed, Inc. stock logo
INSM
Insmed
$141.33
-2.2%
$110.85
$90.39
▼
$212.75
$31.00B0.833.06 million shs6.22 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,297 shs367,682 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.25%-7.42%-25.92%-49.89%+12.01%
Incyte Corporation stock logo
INCY
Incyte
-1.64%-4.79%-0.63%-9.34%+14.36%
Insmed, Inc. stock logo
INSM
Insmed
+20.58%+22.35%+51.00%+14.86%-29.03%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$41.36
-5.2%
$60.06
$37.43
▼
$95.49
$5.85B1.342.27 million shs3.91 million shs
Incyte Corporation stock logo
INCY
Incyte
$114.63
-1.1%
$118.63
$89.25
▼
$132.60
$23.37B0.781.72 million shs1.54 million shs
Insmed, Inc. stock logo
INSM
Insmed
$141.33
-2.2%
$110.85
$90.39
▼
$212.75
$31.00B0.833.06 million shs6.22 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$554.73
-0.8%
$548.85
$455.63
▼
$614.23
$23.63B0.49551,297 shs367,682 shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+1.25%-7.42%-25.92%-49.89%+12.01%
Incyte Corporation stock logo
INCY
Incyte
-1.64%-4.79%-0.63%-9.34%+14.36%
Insmed, Inc. stock logo
INSM
Insmed
+20.58%+22.35%+51.00%+14.86%-29.03%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-3.16%-5.77%+0.94%+8.96%+17.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.73
Moderate Buy$98.71135.36% Upside
Incyte Corporation stock logo
INCY
Incyte
2.44
Hold$133.8615.99% Upside
Insmed, Inc. stock logo
INSM
Insmed
2.92
Moderate Buy$196.5238.03% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4021.69% Upside

Current Analyst Ratings Breakdown

Latest ARWR, INSM, UTHR, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Incyte Corporation stock logo
INCY
Incyte
Set Price TargetHold$115.00
11/17/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$108.00 ➝ $105.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingSell (D-)
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Reiterated RatingOutperform$100.00
11/13/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Lower Price TargetBuy$104.00 ➝ $96.00
11/12/2026
Incyte Corporation stock logo
INCY
Incyte
UpgradeStrong Sell ➝ Hold
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Initiated CoverageBuy$660.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOverweight$700.00 ➝ $703.00
11/5/2026
Incyte Corporation stock logo
INCY
Incyte
Lower Price TargetOutperform$154.00 ➝ $150.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetBuy$675.00 ➝ $700.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$450.82M13.15N/AN/A$0.36 per share116.51
Incyte Corporation stock logo
INCY
Incyte
$5.14B4.58$6.05 per share19.06$27.68 per share4.17
Insmed, Inc. stock logo
INSM
Insmed
$606.42M51.51N/AN/A$3.31 per share43.01
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.19B7.43$31.76 per share17.50$147.36 per share3.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$724.21M-$5.11N/AN/AN/A-160.64%-172.62%-37.51%2/4/2027 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$1.29B$1.8861.4914.614.206.71%7.92%6.12%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$2.82N/A229.64N/A-39.85%-96.38%-32.55%N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5021.0117.343.8438.61%19.18%17.07%N/A

Latest ARWR, INSM, UTHR, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
10/29/2026Q3 2026
Incyte Corporation stock logo
INCY
Incyte
-$3.93-$3.60+$0.33-$3.86$1.46 billion$1.56 billion
10/29/2026Q3 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.3827-$0.46-$0.0773-$0.46$500.36 million$524.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
16.61
4.14
4.11
Incyte Corporation stock logo
INCY
Incyte
N/A
3.84
3.75
Insmed, Inc. stock logo
INSM
Insmed
0.77
2.86
2.59
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Insmed, Inc. stock logo
INSM
Insmed
N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.60%
Incyte Corporation stock logo
INCY
Incyte
16.20%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1,062141.37 million136.28 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844203.83 million170.81 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664219.38 million214.77 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

United Therapeutics Reports First Pig Kidney Transplant in Trial
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,583,530.00 in Stock
United Therapeutics (UTHR) Gets a Hold from Morgan Stanley
FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$41.36 -2.29 (-5.24%)
Closing price 03:59 PM Eastern
Extended Trading
$41.37 +0.01 (+0.02%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Incyte stock logo

Incyte NASDAQ:INCY

$114.63 -1.24 (-1.07%)
Closing price 04:00 PM Eastern
Extended Trading
$114.65 +0.02 (+0.02%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed stock logo

Insmed NASDAQ:INSM

$141.33 -3.13 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$142.28 +0.95 (+0.67%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$554.73 -4.37 (-0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$550.30 -4.43 (-0.80%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.